Patient disposition (by investigator assessment) (N = 321)
| . | No. (%) . |
|---|---|
| Ongoing treatment | 124 (39) |
| Discontinued treatment | 197 (61) |
| Disease progression | 88 (27) |
| Adverse events | 61 (19) |
| Drug related | 50 (16)* |
| Non-drug related | 11 (3) |
| Abnormal test results | 4 (1) |
| Abnormal laboratory values | 2 (< 1) |
| Other† | 39 (12) |
| Death | 3 (< 1) |
| . | No. (%) . |
|---|---|
| Ongoing treatment | 124 (39) |
| Discontinued treatment | 197 (61) |
| Disease progression | 88 (27) |
| Adverse events | 61 (19) |
| Drug related | 50 (16)* |
| Non-drug related | 11 (3) |
| Abnormal test results | 4 (1) |
| Abnormal laboratory values | 2 (< 1) |
| Other† | 39 (12) |
| Death | 3 (< 1) |
Drug-related adverse events causing discontinuation included myelosuppression (n = 20; 6%), elevations of lipase or pancreatitis (n = 2; < 1%), elevations of liver enzymes or bilirubin (n = 3; < 1%), skin disorders (n = 5; 2%), diarrhea (n = 1; < 1%).
Other includes protocol violation, withdrawn consent, lost to follow-up, not stated, and administrative problems.